a tool for structure-function studies of
the MDR1-P-glycoprotein. Curr Protein Pept Sci. Oct;3(5):513-30.
Important Note:
During shipment, small volumes of product will occasionally become
.
4. Shelby, R.D., et al., J. Cell. Biol., 136, 501-513
(1997).
5. Van Hooser, A.A., et al., J. Cell. Sci., 114, 3529-
3542 (2001).
6. Yoda, K., et al., Proc. Natl. Acad. Sci.
1997).
4. Shelby, R.D., et al., J. Cell. Biol., 136, 501-513
(1997).
5. Van Hooser, A.A., et al., J. Cell. Sci., 114, 3529-
3542 (2001).
6. Yoda, K., et al., Proc. Natl. Acad. Sci. USA, 97
2003).
6. Faden, A.I., J. Neurotrauma, 14, 885-895 (1997).
7. Bruno, V., et al., J Neurosci., 20, 6413-6420 (2000).
This product is manufactured by MBL International
Corporation.
BKR,PHC 09/08-1
et al., J. Exp. Med., 158, 1092 (1983).
5. Opdenakker, G. et al., Experimenta (Basel), 45,
513 (1989).
6. Fisher, P. et al., Pharmac. Ther., 27, 143 (1985).
7. Schreiber, R. et al., Lymphokines, 11
6. Faden, A.I., J. Neurotrauma, 14, 885-895 (1997).
7. Bruno, V., et al., J Neurosci., 20, 6413-6420 (2000).
This product is manufactured by MBL International
Corporation.
BKR,PHC 09/08-1
characterization of
up-converting inorganic lanthanide phosphors as
potential labels. J. Fluoresc., 15, 513-28 (2005).
4. Ye, X. et al., Morphologically controlled synthesis of
colloidal upconversion nanophosphors
characterization of
up-converting inorganic lanthanide phosphors as
potential labels. J. Fluoresc., 15, 513-28 (2005).
4. Ye, X. et al., Morphologically controlled synthesis of
colloidal upconversion nanophosphors
characterization of
up-converting inorganic lanthanide phosphors as
potential labels. J. Fluoresc., 15, 513-28 (2005).
4. Ye, X. et al., Morphologically controlled synthesis of
colloidal upconversion nanophosphors
characterization of
up-converting inorganic lanthanide phosphors as
potential labels. J. Fluoresc., 15, 513-28 (2005).
4. Ye, X. et al., Morphologically controlled synthesis of
colloidal upconversion nanophosphors
characterization of
up-converting inorganic lanthanide phosphors as
potential labels. J. Fluoresc., 15, 513-28 (2005).
4. Ye, X. et al., Morphologically controlled synthesis of
colloidal upconversion nanophosphors
characterization of
up-converting inorganic lanthanide phosphors as
potential labels. J. Fluoresc., 15, 513-28 (2005).
4. Ye, X. et al., Morphologically controlled synthesis of
colloidal upconversion nanophosphors
characterization of
up-converting inorganic lanthanide phosphors as
potential labels. J. Fluoresc., 15, 513-28 (2005).
4. Ye, X. et al., Morphologically controlled synthesis of
colloidal upconversion nanophosphors
characterization of
up-converting inorganic lanthanide phosphors as
potential labels. J. Fluoresc., 15, 513-28 (2005).
4. Ye, X. et al., Morphologically controlled synthesis of
colloidal upconversion nanophosphors
characterization of
up-converting inorganic lanthanide phosphors as
potential labels. J. Fluoresc., 15, 513-28 (2005).
4. Ye, X. et al., Morphologically controlled synthesis of
colloidal upconversion nanophosphors
characterization of
up-converting inorganic lanthanide phosphors as
potential labels. J. Fluoresc., 15, 513-28 (2005).
4. Ye, X. et al., Morphologically controlled synthesis of
colloidal upconversion nanophosphors
amino acid residues 382
to 513) expressed in mouse myeloma NSO cells.1
Mature human BMP-6, generated after the proteolytic
removal of the signal peptide and the propeptide, is a
disulfide-linked homodimeric
................. ........................ D 6581–08 A.
Electrolytically Suppressed Ion Chromatography ............ ........................ D 6581–08 B.
Chlorite ................................ Chemically
631-638 (1996).
42. Morigi, M. et al., Stem Cells, 28, 513-522 (2010).
U.S. Patent #5,665,328
Distributed for Phanos Technologies.
RC,PHC 08/12-1
2012 Sigma-Aldrich Co. LLC. All rights reserved
631-638 (1996).
42. Morigi, M. et al., Stem Cells, 28, 513-522 (2010).
U.S. Patent #5,665,328
Distributed for Phanos Technologies.
RC,PHC 08/12-1
2012 Sigma-Aldrich Co. LLC. All rights reserved
631-638 (1996).
42. Morigi, M. et al., Stem Cells, 28, 513-522 (2010).
U.S. Patent #5,665,328
Distributed for Phanos Technologies.
RC,PHC 08/12-1
2012 Sigma-Aldrich Co. LLC. All rights reserved
Chemokines induce eosinophil degranulation through CCR-3. J.
Allergy Clin. Immunol. 106: 507–513.
2. Fulkerson PC et al. (2006) A central regulatory role for eosinophils and the eotaxin/CCR3 axis
by AKT To Regulate
MYC-Dependent Apoptosis and Transformation. Mol Cell Biol 2013 Feb; 33(3):498-513.
3. Shubbar E et al. Elevated cyclin B2 expression in invasive breast carcinoma is associat-
ed with
smartflare
A. B. C.
105 40
30
20
0
104
103
102
101
100
101100 102 103
488-513/26-Height-Log
miR-222-Cy5 in Mixed Population
Gelatin; % degradation area
of total cell area